Marianna Rowlands, PhD

Associate Director
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Inhibition of Relevant Clinical and Pathway Biomarkers in Patients with COVID-19 Pneumonia and Inflammation in a Phase 2 Multicenter Randomized Study with MAS825, an Anti-IL-1β/IL-18 Bispecific Monoclonal Antibody

  Wednesday, June 22, 2022
  1:25 PM – 1:40 PM PT

• B Cell Subsets as Severity-associated Signatures in COVID-19 Patients

  Wednesday, June 22, 2022
  3:15 PM – 3:30 PM PT

• CGC+ CD4+ T Cells are Cytomegalovirus Specific Cells that are Biomarkers of Cardiometabolic Disease Risk in Persons with HIV

  Wednesday, June 22, 2022
  3:30 PM – 3:45 PM PT

• Fc Structure and Function of Antibodies Elicited by COVID-19 mRNA Vaccine and Infection

  Wednesday, June 22, 2022
  3:45 PM – 4:00 PM PT

• Immunological Profiles of HIV-infected and Uninfected Patients Admitted with COVID-19 in Tshwane

  Wednesday, June 22, 2022
  4:00 PM – 4:15 PM PT

• Interferon Gamma Induction of TH1-like Tregs Dampens Anti-viral Responses

  Wednesday, June 22, 2022
  4:15 PM – 4:30 PM PT

• Platelet Activation Through TRPC6 Mediates Cystic Fibrosis Lung Inflammation and Injury

  Wednesday, June 22, 2022
  4:30 PM – 4:45 PM PT

• Severe Mycobacterial Immune Reconstitution Inflammatory Syndrome can cause Secondary Hemophagocytic Lymphohistiocytosis with a Unique Immune and Genetic Profile

  Wednesday, June 22, 2022
  4:45 PM – 5:00 PM PT

• Tolerogenic Dendritic Cells Engineered with a Lentiviral Vector Encoding for IL-10 and Antigen Control T Cell Responses to Pathogenic Antigens

  Wednesday, June 22, 2022
  5:00 PM – 5:15 PM PT